Christopher John Kenney insider trades: Xenon Pharmaceuticals (XENE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Christopher reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | XENE | ↓ Sell | 7,068 | $60.25 | $426K | Direct | Aug 31, 2026 (3d) |
| Mar 13, 2026 | XENE | ↓ Sell | 1,410 | $55.23 | $78K | Direct | Mar 13, 2026 (0d) |
| Mar 10, 2026 | XENE | ↓ Sell | 2,771 | $60.11 | $167K | Direct | Mar 11, 2026 (1d) |
| Mar 24, 2023 | XENE | ↓ Sell | 700 | $35.01 | $25K | Direct | Mar 24, 2023 (0d) |
| Jan 21, 2022 | XENE | ↑ Buy | 700 | $28.81 | $20K | Direct | Jan 21, 2022 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other XENE insiders
Open-market trades in the last 12 months
About Christopher John Kenney's insider trades
Christopher John Kenney is Chief Medical Officer at Xenon Pharmaceuticals (XENE). Since Jan 21, 2022, Christopher has reported 1 open-market purchase worth $20K and 4 sales worth $695K on SEC Form 4. In the last 12 months: 3 sales ($670K).
Their filings also include grants and awards (6 filings), option exercises (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every XENE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.